Perifosine

Perifosine is an oral Akt inhibitor which inhibits proliferation of different tumor cell lines with IC50s of 0.6-8.9 μM.

Product Specifications

CAS Number

[157716-52-4]

Product Name Alternative

KRX-0401; NSC 639966; D21266

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; Apoptosis; Autophagy

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Perifosine.html

Purity

99.91

Solubility

DMF : < 1 mg/mL|DMSO : < 1 mg/mL|H2O : 100 mg/mL (ultrasonic)

Smiles

[O-]P(OC1CC[N+](C)(CC1)C)(OCCCCCCCCCCCCCCCCCC)=O

Molecular Formula

C25H52NO4P

Molecular Weight

461.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Momota H, et al. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res, 2005, 65 (16), 7429-7435.|[2]Vyomesh Patel, et al. Perifosine, a novel alkylphospholipid, induces p21 (WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res, 2002, 62 (5), 14|[3]Chen L, et al. Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures. Epilepsia. 2012 Nov;53 (11) :2026-33.